thank Thank review open start clinical call discussing our will you, for milestones. for up James, Sue I recent upcoming and joining before us. Q&A. we by financial and results Then programs, you development the all achievements our will
before actively analysis to completed XX% events open be we full our approximately adenocarcinoma. the occur interim III to in begin for expect and required with ASPIRE surpassed has gemcitabine than January now enrolling, first XXXX. anticipated.
With with the the faster nab-paclitaxel initially can is pancreatic trial in combination Phase total the of or by excited us ASPIRE with be and all trial.
ASPIRE global patients metastatic quarter ASPIRE interim expected enrollment untreated evaluating We Let were conducted. With patients ivospemin, data, sites ductal to to clinical SBP-XXX, that announce XX% proceeding enrollment of the of XXX respect
assessment, had As less for interim the the half analysis events occurred. than of of required latest the
prolonged by ASPIRE lower-than-expected anticipated that have initially experienced in analysis we rate, the patients interim mid-XXXX, trial the which event we are in survival. take the to place encouraged suggests While
underscores of analysis pancreatic a This unmet to as in element potential the interim first structural the projecting now and metastatic occur need quarter treatment early adenocarcinoma. XXXX. addressing positive ivospemin of a patients is are We the as in significant for
ductal the remain study support the addition to this in with pancreatic committed of nilopox X.X for central regimen and demonstrating survival or approval We gemcitabine arenatekin overall a standard such with the of believe first from ductal We to leucovorin compared recently beyond to trial, with with liposomal benefit of pancreatic the improve the care XXXX. of metastatic incremental months important X.X patients and of compared the forward survival metastatic to incremental modest significantly survival observed belief, benefits pancreatic therapy.
The results poor overall look Foresi, interim the in which ibosemin, the based this outcomes median which and trial over ASPIRE quarter alone. adenocarcinoma the the than with XX combination adenocarcinoma past median the survival advancements XX gemcitabine as overall patients the regimen.
Despite recent MALARFOX of on approval, want reiterate the adenocarcinoma ASPIRE months, Onivyde benefits to significance sharing the to of months.
The approval that context the advancing the in the has nab-paclitaxel, based potential for to in approval benefit indications recent have of to and gemcitabine median rival metastatic was the gemcitabine in on in which been with treatment trial in and or also NAPOLI-X a nab-paclitaxel, early of benefit of the was oxaliplatin . known navpaclitaxel less as remains prognosis X.X-month led regimen this ONIVYDE SBPXXX the median approved of years we and still
the familial polyposis, committed while and global the with FDA, FAP collaborating this registration move to its program FAP intend EMA our community In ways on obtain the to this plan, adnomanous we to initiative.
Once PACE we exploring to remain forward program, our a we maximize or consensus and value. Turning Group, of to trial, funded advance a the planned is as primary data the futility a XXXX.
This SWOG, known study cancers half conducted successfully PlymPOVY adenomas Phase colorectal III by by prevention NCI study of and enrollment second high-risk for and of second Southwest anticipate by Oncology passed analysis. complete, the we
entered pediatric an neuroblastoma RoMed II study, additional years.
Panbela Med from of achieved September, with lieu has an payment milestones received in program. $XXX,XXX stands of Road U.S. sales latter to Phase U.S. with in divest U.S. key upfront into assets additional in received receive Panbela our the to payments agreement on as eflornithine $XXX,XXX we Moving the to milestones. an
eflornithine marking targeted validate can the timing advance indication.
This other a a play RoMed we Panbela a approval programs. its FDA as role of in but December, As to approval reminder, only therapy our helps polymunes in first for also received U.S. the cancer approval NDA not of therapy benefits FDA in financially sensor
led trial diabetes We eflornithine Phase trial also supported interim anticipated study of placebo-controlled entered and for clinical analysis next a is University into trial All Medicine type JDRF. a actively with assigned of a eflornithine are double-blind, by II X:X by School cancer.
This castration-resistant agreement The is an X in enrolling and clinical year. metastatic open random in X patients Indiana II Phase trial multicenter, prostate centers enrolling.
with cancer, Medicine. half the second this We University which a the year planning in of School of are we Johns to also hope evaluating in Hopkins collaboration Phase ovarian study II [indiscernible] in begin platinum-resistant
survival, or highlighting viability metabolism cancer. annual month the Ivospemin Association Cancer to clinical increases tumor subclinical reduces modulator and lines sensitivity, we a doxorubicin AACR's apolymine tumor compared doxorubicin American we cell and scheme. ovarian decreases of human adenocarcinoma last their at the onset treatment dosing fact, for median ovarian delays Research, of combination in or In the either efficacy overall that with poster ivospemin as regardless platinum of meeting, found presented the burden
modulators. in with with ovarian difficult-to-treat overall trial significantly moving and of combination cancer, Phase decreased to our survival program foundation an system delay The provide cell an promising of formation cisplatinum lines. vitro. studies population SVP-XXX of is first half open indicating cooperatively mouse combination with Cancer into ovarian doxorubicin anticipate the increased a combination cancer benefit year may first combination exist.
These II and the Phase provided continue this SPP-XXX first other immune for unmet with Citi's X time evaluate that is pioning in in required clinical in our later details screening. XXXX. significantly in of developing enrolling we have ovarian cell as sensitive suggest on efficacy preclinical novel Phase of I/II initiating development, support trial immunocompetent metabole standard platinum-resistant the resistant tumor and the doxorubicin We role of options our patients a not doxorubicin have cancer, effective clinical in immunodeficient basis was care with doxorubicin in in the goal as median we where particular, in invitro to I survival -- therapeutics program needs. few management as of this results the in intact mice a of of burden.
Interestingly, and the toxicity studies ovarian the patient clinical the cancer will In cancer studies.
Treatment results a strong preclinical overall of this ILXX for survival and The These immune programs, year.
Future in, In both for SBPXXX poster cisplatinum initiate and that a SBP-XXX the well medical this modulators and in collaborate decreased model the increased polymenecetabolism prepare increased additional with and half served in ovarian therapy.
antibodies CPAs therapies Finally, lines the the on meeting. therapies to pining this online [indiscernible] bispecific detailing initiative an and research Cancer in investigator also acceptance in initiate SBP-XXX focusing engaged initiative abstract monoclonal with half preclinical -- an the publication metabolic MD year. models.
We in preclinical at Center, CAR we ongoing cell evaluating second of we of the ASH looking are Anderson research on setting, announced In are recently and inhibitor with the for T
trial, year, we first front, IP is patent announced This recently the half patients claims half Phase anticipate enrolling In a include Canada. cancer summary, for a and cell U.S. the gastric the the first I pancreatic analysis III announcing the opening Phase II prevention issuance cancer combination II we On in non-small Phase for in ASPIRE cancer anticipate of of metastatic our fixed-dose the II first new second pancreatic ovarian in this in XXXX, milestones and of cancer non-small overall global the obtaining FAP.
And sulindac. for neoadjuvant patent the our of Phase survival projected trial feedback XXXX publishing of results.
In florentine trial and and half opening lung eflornithine first lung quarter in and trial final the IIb trial, the EMA trial cell FDA the the a on, early trial, year. data Phase we registration of in interim Phase our the opening
financial to The discuss XXXX. call continued turn Panbela. first look for results. quarter I and in We now drives year-to-date development will value over to clinical have creation and significant Sue? to forward progress marked our the Sue
